How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors

Earlier this week, Bristol Myers Squibb reported positive Phase 3 results for three key programs: RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, admilparant in idiopathic pulmonary fibrosis where only the lower dose met the primary endpoint, and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. Together, these late-stage readouts highlight both the promise and complexity of Bristol Myers Squibb’s next generation portfolio, with new oncology,...